Our Investor Proposition

Unlocking value for our shareholders

Our growing commercial business is funding Valneva’s exciting R&D pipeline

Stock Information

€2,90 +1,76% Last update: January 20, 2020 at 17:35 CET Stock Price
“We have the only clinical-stage vaccine program against Lyme disease worldwide.”
Valneva's CEO Thomas Lingelbach comments on Group Strategy

2020 J.P. Morgan Healthcare Conference

Access Valneva's 2020 J.P. Morgan Healthcare Conference Presentation

View More

Upcoming Events

January 28, 2020

Biomed Event by Invest Securities

February 27, 2020

Unaudited FY 2019 Results

View Calendar

First nine-month results 2019

View More

Contact

Investor Relations Team

Campus Bio-Ouest
6, Rue Alain Bombard
44800 Saint-Herblain, France
T: +33 2 28 07 37 10 investors@valneva.com

Subscribe to Valneva News

Submit

Press Releases

View More